Skip to main content
. 2020 Nov 11;8(11):e22006. doi: 10.2196/22006

Table 2.

Description of wearables and adherence.

Planned wear time interval and study (year) Hardware / software Device outcome Planned wear time / valid wear time Adherence description
≤7 days




Chevalier et al (2003) [19] Actigraph, Ambulatory Monitoring Inc / Action 3.8

  • Rest activity cycle (movements/period)

 3 days / 3 days

  • 100% (10/10) of the patients wore the device for the full period

Dean et al (2013) [20] Motionlogger actigraph / Action 3

  • Sleep efficiency (%)

  • Sleep (hours)

  • Wake after sleep onset (minutes)

 7 days / not reported

  • 86% (30/35) of the patients wore the device for the full period

Lowe et al (2014) [26] activPALa / not reported

  • Position time (hours/day)

  • Energy expenditure (metabolic equivalent of task [MET] h/day)

  • Step count (steps/day)

 7 days / not reported

  • 77% (24/31) of the patients provided evaluable sensor data between 3 and 7 days

Roscoe et al (2002) [34] Mini-Motionlogger Actigraph / Action 3

  • Circadian consistency (I<Ob)

  • Daytime activity level (minutes)

  • Sleep (%)

 72 hours at 2 timepoints / not reported

  • 89% (91/102) provided evaluable sensor data at second cycle of chemotherapy

  • 44% (45/102) provided evaluable sensor data at fourth cycle of chemotherapy

Vassbakk-Brovold et al 2016) [39] SenseWear Armband Pro3 or SenseWear Armband Minia / SenseWear version 6.1 for Pro3 and version 7.0 for Mini

  • Physical activity (minutes/week) recorded in 1-minute epochs

 5 days / ≥19.2 hrs, for ≥1 day

  • 79 % (66/84) of the patients wore the device for the full period
8-30 days




Edbrooke et al (2019) [22] SenseWear accelerometera / not reported

  • Step count (steps/day)

  • Number of 10+ minutes step bouts/day

  • Duration of 10+ minutes bouts (minutes)

  • Cadence of 10+ minutes bouts (steps/min)

 7 days at 3 timepoints / 8hrs/day, for ≥4 days

  • 87% (80/92) of the patients provided evaluable sensor data at baseline

  • 71%(65/92) of the patients provided evaluable sensor data at 9 weeks

  • 60% (55/92) of the patients provided evaluable data at 6 months

Innominato et al (2016) [24] Micro Motionlogger / Action 4

  • Circadian rest-activity (I<Ob)

 30 days / not reported

  • Evaluable sensor data were available in 75 % of the total days (653/874)

Li et al (2019) [25] GENEActiv Original / not reported

  • Sleep efficiency (%)

  • Sleep duration (minutes)

  • Nighttime total wake time (minutes)

 7 days at 3 timepoints / ≥5 days per timepoint

  • 97% (175/180) of the patients provided evaluable sensor data at T2

  • 76% (136/180) of the patients provided evaluable sensor data at T3

Low et al (2017) [11] Fitbit Charge HR / not reported

  • Step count (steps/day)

  • Floors climbed (n)

  • Sleep (minutes)

  • Awakenings (n)

  • Time in bed (minutes)

 4 weeks / not reported

  • Evaluable sensor data were available in 75 % of the total days (295/392 days)

Mouri et al (2018) [27] Kenz Lifecorder‐GSa / Lifelyzer‐05 coach

  • Step count (steps/day)

  • Physical activity (minutes/day) (physical activity was rated ≥1.8 METs)

 7 days at 3 timepoints / ≥5 hrs/day

  • 93% (28/30) of the patients wore the device for the full period

Ohri et al (2019) [29] Garmin Vivofit a / not reported

  • Step count (steps/day)

 Up to 3 weeks / not reported

  • Evaluable sensor data were available in 94 % of the total days (741/791)

Ortiz-Tudela et al (2014) [31] Mini-Motionlogger Actigraph / Action 4

  • Rest-activity (I<Ob)

  • Wrist accelerations (acc/minute)

 10-14 days split into 4 periods of 3-4 days / not reported

  • 86% (42/49) of the patients provided evaluable sensor data the full period

Roche et al (2014) [33] Mini-Motionlogger and VitalSense / Action 4, version 1.10

  • Rest-activity (I<Ob)

  • Wrist accelerations (acc/minute)

  • Skin surface temperature (°C/minute)

 12 days split into 3 periods of 4 days/ not reported

  • 100% (16/16) of patients provided evaluable sensor data at baseline

  • 63% (10/16) of patients provided evaluable sensor data during therapy and after therapy administration

Sarna et al (2001) [35] Actiwatch 2 / not reported

  • Wrist movement (n/second)

  • Physical activity (15-minute intervals)

 5 days at 2 timepoints/ ≥3 days per timepoint

  • 100% (7/7) of the patients wore the device the full period

Savard et al (2009) [36] Actillume / Action 3

  • Circadian rhythm variables (calculated from orientation and movement)

 72 hrs at 7 timepoints/ not reported

  • 91% (86/95) of patients provided evaluable sensor data at baseline (first cycle of chemotherapy week 1: 80%, week 2: 73% and week 3: 76%; fourth cycle of chemotherapy week 1: 74%, week 2 63% and week 3: 68%)

Solk et al (2019) [37] ActiGraph, model wGT3X-BT / ActiLife, version 6.13.3

  • Activity data (1-minutes intervals)

 10 days at 3 timepoints / ≥10 hrs/day

  • 84% (63/75) of the patients provided evaluable sensor data for the full period

van der Meij et al (2012) [38] PAM accelerometer, model AM101a / not reported

  • Physical activity (index score, 3 points reflects about 10 min of walking)

 7 days at 3 timepoints / ≥3 full days

  • 65% (26/40) of the patients wore the device for the full period

Wright et al (2018) [40] Fitbit Zip and Fitbit Charge 2 / Fitabase

  • Step count (steps/day)

  • Heart rate

 30 days / ≥4 days/week

  • 90% (9/10) of the patients wore the devices for the full period
31-90 days




Broderick et al (2019) [17] Microsoft Band 2 / not reported

  • Step count (steps/day)

  • Heart rate

  • Calories (calories/hour)

 60 days / ≥6 hrs/day

  • Evaluable sensor data were available 86 % of the days (only day 1-14 included)

Champ et al (2018) [18] Misfit Shinea / not reported

  • Step count (steps/day)

  • Calories (calories/day)

  • Walking distance (miles)

  • Sleep (hours)

 10 weeks / not reported

  • 90% (9/10) of the patients wore the device for the full period

Gupta A et al (2018) [23] Fitbit Flex / not reported

  • Step count (steps/day)

  • Physical activity (sedentary minutes/day)

  • Sleep (minutes)

 12 weeks / ≥1 steps/day recorded

  • 96% (23/24) wore the device for >50% of the period

Nyrop et al (2018) [28] Fitbit Zipa / not reported

  • Step count (steps/day)

 6-12 weeks / ≥3 weeks

  • 79% (100/127) of the patients provided evaluable sensor data

Ohri et al (2017) [30] Garmin / not reported

  • Step count (steps/day)

 Up to 80 days / 80% of the days

  • Evaluable sensor data were available 94 % of the days
>91 days




Dreher et al (2019) [21] Fitbit Charge HR or Fitbit Charge 2 / Fitabase

  • Step count (steps/day)

  • Heart rate

  • Sleep data

 Up to 270 days / ≥10 hrs/day

  • Evaluable sensor data were available in 45% of the days across 9 months

Parker et al (2019) [32] ActiGraph GT3X+a / ActiLife Software, Version 6

  • Physical activity (minutes/week) (1-min epochs)

 14 days at each therapy phase / ≥10 hrs/day, for ≥7 days per timepoint

  • 88 % (44/50) of the patients provided evaluable sensor data

aPlacement other than wrist (anterior mid-thigh, hip, triceps muscle waist, not reported).

bbI<O is computed as the percentage of activity epochs when in-bed (I), whose values are lower than the median level of activity when out-of-bed(O).